Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

BDKRB2 Antikörper (C-Term, Intracellular)

Der Kaninchen Polyklonal anti-BDKRB2 Antikörper (ABIN7886089) detektiert spezifisch BDKRB2 in WB, IHC, IF und IC. Dieser Antikörper reagiert spezifisch mit Proben aus Human.
Produktnummer ABIN7886089
1.184,62 €
Zzgl. Versandkosten 20,00 € und MwSt
Lieferung nach: Deutschland
Lieferung in 8 bis 9 Werktagen

Kurzübersicht für BDKRB2 Antikörper (C-Term, Intracellular) (ABIN7886089)

Target

Alle BDKRB2 Antikörper anzeigen
BDKRB2 (Bradykinin Receptor B2 (BDKRB2))

Reaktivität

  • 49
  • 47
  • 24
  • 2
Human

Wirt

  • 62
  • 4
Kaninchen

Klonalität

  • 42
  • 24
Polyklonal

Konjugat

  • 22
  • 4
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Dieser BDKRB2 Antikörper ist unkonjugiert

Applikation

  • 46
  • 19
  • 13
  • 13
  • 13
  • 10
  • 8
  • 5
  • 3
  • 3
  • 3
  • 2
Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunochromatography (IC)
  • Bindungsspezifität

    • 16
    • 6
    • 5
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    AA 336-349, C-Term, Intracellular

    Verwendungszweck

    A Rabbit Polyclonal Antibody to B2 Bradykinin Receptor

    Kreuzreaktivität

    Human, Maus, Ratte

    Homologie

    mouse - 11,Rat - 12,13 amino acid residues identical

    Produktmerkmale

    Anti-B2 Bradykinin Receptor (BDKRB2) Antibody (ABIN7042968, ABIN7043942 and ABIN7043943) is a highly specific antibody directed against an epitope of the human protein. The antibody can be used in western blot, immunohistochemistry, and immunocytochemistry applications. It has been designed to recognize B2R from human, rat, and mouse samples.

    Aufreinigung

    Affinity purified on immobilized antigen.

    Immunogen

    GKRFRKKSWEVYQG(C), corresponding to amino acid residues 336-349 of human B2R

    Isotyp

    IgG
  • Applikationshinweise

    WB: 1:1000

    FC: The optimal concentration should be determined by the user

    ICC: The optimal concentration should be determined by the user

    IHC: The optimal concentration should be determined by the user

    IP: The optimal concentration should be determined by the user

    Kommentare

    Cited Application: IHC

    Negative Control: (ABIN7234872)

    Blocking Peptide: (ABIN7234872)

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Lyophilized

    Rekonstitution

    25 μL, 50 μL or 0.2 mL double distilled water (DDW), depending on the sample size.

    Konzentration

    0.8 mg/mL

    Buffer

    PBS pH 7.4, 1 % BSA with 0.05 % sodium azide

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Lagerung

    -20 °C

    Informationen zur Lagerung

    The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C
  • Target

    BDKRB2 (Bradykinin Receptor B2 (BDKRB2))

    Andere Bezeichnung

    BDKRB2

    Hintergrund

    Synonyms: B2R, BKR2, B2BKR, BKRB2, Kinin B2, BRADYB2

    Description: Kinins are small peptides produced rapidly following tissue injury that serve as important modulators of inflammation and pain. In the periphery, the actions of kinins include vasodilatation, increased vascular permeability, stimulation of immune cells, and induction of pain. Kinins in the central nervous system (CNS) seem to initiate a similar cascade of events leading to neural tissue damage, as well as long lasting disturbances affecting blood-brain barrier function.1Kinins, such as Bradykinin (BK), Lys-BK, desArg9-BK, and Lys-desArg9-BK, exert their action via two distinct receptors: the B1 Bradykinin receptor (BKRB1) and the B2 Bradykinin receptor (BKRB2). BKRB2 is activated by BK and Lys-BK while desArg9-BK and Lys-desArg9-BK activate BKRB1.2 Activation of BKRB2 liberates mediators of vascular tone, fibrinolysis, and pain. BKRB2, which mediates most of the physiological effects of kinins, as well as BKRB1, represent potential therapeutic targets for treatment of inflammatory disorders and cardiovascular diseases.Both BKRB1 and BKRB2 are members of the seven-transmembrane domain, G protein-coupled receptor (GPCR) superfamily and share a common structure of seven putative transmembrane domains, an extracellular amino terminus, and a cytoplasmic carboxy terminus.BKRB2 is constitutively and widely expressed throughout the CNS and peripheral nervous system and on various cell types including endothelial cells, nerve fibers, leukocytes, and mast cells.3-5

    Gen-ID

    624

    NCBI Accession

    NM_000623

    UniProt

    P30411

    Pathways

    ACE Inhibitor Pathway, Negative Regulation of intrinsic apoptotic Signaling
Sie sind hier:
Chat with us!